|
|
| Finding and contracting CDMOs who are ready, willing, and able can present challenges for sponsor companies who are developing and manufacturing a novel therapeutic. Outsourced Pharma is helping address these difficulties. The Outsourced Pharma Capacity Update (OPCU) brings together the industry’s leading CDMOs to present real-time and direct information on their available capacity and services, as well as provide specific facility and equipment news. Discover the May 2024 event’s Cell & Gene Therapy and Fill/Finish presenting sponsors in this newsletter and learn how they are best suited to help you to navigate the path to approval and commercialization. The OPCU offers a unique forum where you can connect with the CDMOs suited for your project’s needs, all from the comfort of your desk. Find the right development and manufacturing partner at the upcoming OPCU in July 2024. Registration is free at the links below. - Monday, July 22, 2024 - Fill/Finish
- Tuesday, July 23, 2024 - Large Molecule Development
- Wednesday, July 24, 2024 - Small Molecule API & HPAPI Development
- Wednesday, July 24, 2024 - Small Molecule Finished Dosage Form
- Thursday, July 25, 2024 - Cell & Gene Therapy
|
|
|
|
Novartis Contract Manufacturing | Learn more about our integrated offerings in mammalian drug substance and drug product. Our drug product (Fill & Finish) services cover vials (LivI, Lyo), syringes (PFS), Cartrdiges and Auto Injectors. | Request Information | Novartis Contract Manufacturing |
|
|
Resilience | Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Hear about how we can support manufacturing programs from clinical through commercial. | Request Information | Resilience US, Inc. |
|
|
IDT Biologika | We are a sustainable partner in the commercial manufacturing of your liquid products. To advance therapeutic and prophylactic therapies, we have set up state-of-the-art high-speed filling capacities. | Request Information | IDT Biologika |
|
|
Pfizer CentreOne | Senior Business Development Manager, Christine Rodi, highlights our overall sterile injectable drug substance capabilities, with a focus on our ability to help meet your complex sterile injectable needs. | Request Information | Pfizer CentreOne |
|
|
|
Comprehensive Cell Solutions | We are a CGT focused division of New York Blood Center Enterprises with a Draw-To-Thaw™ portfolio of CDMO services strategically located throughout the US built upon on NYBC’s 60+ years of experience. | Request Information | Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises |
|
|
Resilience | With a strong network of 11 sites located across North America supporting 5 modalities, Resilience provides innovative solutions and services for established and emerging therapies. | Request Information | Resilience US, Inc. |
|
|
MilliporeSigma | Discover how we apply our 30 years of experience to enhance quality, de-risk viral vector production at any stage, and advance cell and gene therapies from pre-IND through routine supply. | Request Information | MilliporeSigma |
|
|
Cellistic | Examine the time saving factor of using Cellistic's predeveloped Pulse & Echo platforms, the IP considerations with iPCSs, and Cellistic's involvement in developing clinical therapies. | Request Information | Cellistic |
|
|
Andelyn Biosciences | Learn how our proven methodology and decades-long AAV database at the core of the AAV Curator™ Platform directly drives speed, maximizes yields, and delivers a high-quality product. | Request Information | Andelyn Biosciences |
|
|
Pfizer CentreOne | Review our gene & cell therapy capabilities, with a focus on our ability to help meet your complex viral vector needs by employing cutting edge technology with industry leading yield & productivity ratios. | Request Information | Pfizer CentreOne |
|
|
WuXi Advanced Therapies | Review an update on our 400,000+ square foot campus in Philadelphia, Pennsylvania and the infrastructure dedicated to Cell & Gene Therapy development, testing and manufacturing. | Request Information | WuXi Advanced Therapies |
|
|
Aldevron | Explore the new capacity and capabilities of our complete mRNA Ecosystem to offer streamlined services for process development, manufacture, and release of both mRNA drug substance and product. | Request Information | Aldevron |
|
|
Vernal Biosciences | Examine our platform analytical and process technologies designed to accelerate the development of your cell therapy, gene therapy, or vaccine drug product. | Request Information | Vernal Biosciences |
|
|
ReciBioPharm | Learn more about our global capabilities in Nucleic Acid, AAV, Lentivirus, Microbiome and Fill-Finish. We offer end-to-end GMP manufacturing under one roof through an integrated supply chain. | Request Information | ReciBioPharm |
|
|
Theragent | Gain insight into our proprietary digital platform that de-risks clinical trials, expedites manufacturing, offers full transparency to sponsors, and provides complete chain-of-custody assurance. | Request Information | Theragent |
|
|
|
|
| Streamline your search for the ideal CDMO partner at the July 2024 OPCU virtual event! Registration is open now, offering you the opportunity to connect with numerous CDMOs in a single day and avoid the hassle of an extended vetting process. For your convenience, OPCU is grouped by molecule type. You can register for the session(s) highlighting the CDMOs equipped to meet your company's development and manufacturing needs. - Monday, July 22, 2024 - Fill/Finish | Free Registration
- Tuesday, Jult 23, 2024 - Large Molecule Development | Free Registration
- Wednesday, July 24, 2024 - Small Molecule API & HPAPI Development | Free Registration
- Wednesday, July 24, 2024 - Small Molecule Finished Dosage Form | Free Registration
- Thursday, July 25, 2024 - Cell & Gene Therapy | Free Registration
|
|
|